查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529698

类风湿性关节炎治疗市场规模、份额、趋势分析报告：按分子、销售管道、地区、细分市场预测，2024-2030

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

类风湿性关节炎治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新研究，预计到2030年，全球类风湿性关节炎治疗市场规模将达363.9亿美元，2024年至2030年复合年增长率为5.93%。

预测期内复合年增长率将为 4.6%。推动市场的主要趋势包括新型生技药品的可用性、潜在临床候选药物数量的增加以及人口老化的加剧。因此，更安全药物的供应和意识的提高预计将促进类类风湿性关节炎治疗市场的成长。

类风湿性关节炎影响着世界上约 1% 的人口。这种疾病有多种症状，包括关节疼痛、肿胀和僵硬，通常伴随慢性疼痛和无法进行日常活动。随着时间的推移，这种疾病会干扰患者的运动能力并导致关节永久性损伤。如果不及时治疗，这种疾病可能会导致运动障碍和关节关节重建手术的风险。

该疾病盛行率的不断上升、生技药品和生物仿製药的出现以及明确的监管指南将为市场提供动力。根据关节炎基金会的数据，美国65 岁以下的人中有 64% 可能患有关节炎。据估计，已开发地区对疾病缓解治疗的认识不断提高以及医疗保健成本不断上升将推动收益成长。

目前治疗类风湿性关节炎的药物包括JAK抑制剂和IL-6拮抗剂等新型生技药品，以及非类固醇消炎剂（NSAID）和皮质类固醇等学名药，这些药物在已开发国家被广泛使用。Infliximab、Adalimumab生物相似药等新产品的上市预计将利好市场。此外，礼来公司的 Olumiant 和艾伯维公司的 Upadacitinib 也有望降低疾病復发的可能性。

类风湿性关节炎治疗市场报告亮点

  • 生物製药领域引领市场，2023年占全球销售额的88.73%。生物製药是从生物资源製造、提取或合成的高分子药物。
  • 处方药以2023年89.64%的市场占有率领先市场。随着风湿症医师咨询的增加，处方药领域预计将在预测期内保持在类风湿性关节炎治疗市场的主导地位。
  • 2023年北美类风湿性关节炎治疗市占52.31%。由于人口结构的变化、医学研究的进步、监管的变化以及对个人化医疗的日益重视，该区域市场持续成长和发展。
  • 在类类风湿性关节炎盛行率不断上升、医疗基础设施改善以及治疗选择不断进步的推动下，亚太地区类类风湿性关节炎治疗市场正在显着增长。

目录

第一章调查方法和范围

第二章执行概述

第三章类风湿性关节炎治疗市场变数、趋势与范围

  • 类风湿性关节炎治疗市场的系统展望
    • 母市场展望
    • 辅助市场展望 - 骨关节炎治疗市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 类风湿性关节炎治疗市场分析工具
    • 波特五力分析
    • PESTLE分析

第 4 章 2018-2030 年类风湿性关节炎治疗市场分析（按分子）（百万美元）

  • 类风湿性关节炎治疗：分子变异分析
  • 类风湿性关节炎治疗市场分析：依分子分类
    • 生物製药
    • 药品

第 5 章类风湿性关节炎治疗市场分析，按销售管道，2018-2030 年（百万美元）

  • 类风湿性关节炎治疗：销售管道波动分析
  • 类风湿性关节炎治疗市场分析：依销售管道
    • 处方药
    • 非处方药 (OTC)

第六章类风湿性关节炎治疗市场：按分子和销售管道分類的区域估计和趋势分析

  • 类风湿性关节炎治疗市场：区域展望
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • AbbVie, Inc.
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • UCB SA
    • Johnson &Johnson Services, Inc.
    • AG Amgen, Inc.
    • Lilly（Eli Lilly and Company）
Product Code: GVR-2-68038-313-3

Rheumatoid Arthritis Therapeutics Market Growth & Trends:

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.

Rheumatoid Arthritis Therapeutics Market Report Highlights:

  • Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
  • Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
  • North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
  • The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Sales channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Molecule and Sales Channel Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope

  • 3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of rheumatoid arthritis
      • 3.2.1.2. Launch of novel therapeutic agents
      • 3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
      • 3.2.1.4. Favorable reimbursement policies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
      • 3.2.2.2. Side effects and adverse reactions
  • 3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)

  • 4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
  • 4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
    • 4.2.1. Biopharmaceuticals
      • 4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2. Biologics
      • 4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.2. TNF-a antagonists
      • 4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.3. T-cell inhibitors
      • 4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.4. CD20 antigen
      • 4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.5. JAK inhibitors
      • 4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.6. anti-IL6 biologics
      • 4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3. Biosimilars
      • 4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3.2. CD20 antigen
      • 4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3.4. TNF-a antagonists
      • 4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Pharmaceuticals
      • 4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.2. NSAIDs
      • 4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.3. Analgesics
      • 4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.4. DMARDs
      • 4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.5. Glucocorticoids
      • 4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)

  • 5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
  • 5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
    • 5.2.1. Prescription
      • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Over-the-Counter (OTC)
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel

  • 6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
  • 6.2. North America
    • 6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target Disease Prevalence
      • 6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.2.4. Competitive/Market Scenario
      • 6.2.2.5. Regulatory Framework
      • 6.2.2.6. Reimbursement scenario
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.3.4. Competitive/Market Scenario
      • 6.2.3.5. Regulatory Framework
      • 6.2.3.6. Reimbursement Scenario
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.4.4. Competitive/Market Scenario
      • 6.2.4.5. Regulatory Framework
      • 6.2.4.6. Reimbursement Scenario
  • 6.3. Europe
    • 6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.4. Competitive/Market Scenario
      • 6.3.2.5. Regulatory Framework
      • 6.3.2.6. Reimbursement Scenario
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.3.4. Competitive/Market Scenario
      • 6.3.3.5. Regulatory Framework
      • 6.3.3.6. Reimbursement Scenario
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.4.4. Competitive/Market Scenario
      • 6.3.4.5. Regulatory Framework
      • 6.3.4.6. Reimbursement Scenario
    • 6.3.5. Spain
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.5.4. Competitive/Market Scenario
      • 6.3.5.5. Regulatory Framework
      • 6.3.5.6. Reimbursement Scenario
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.6.4. Competitive/Market Scenario
      • 6.3.6.5. Regulatory Framework
      • 6.3.6.6. Reimbursement Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.7.4. Competitive/Market Scenario
      • 6.3.7.5. Regulatory Framework
      • 6.3.7.6. Reimbursement Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.8.4. Competitive/Market Scenario
      • 6.3.8.5. Regulatory Framework
      • 6.3.8.6. Reimbursement Scenario
    • 6.3.9. 6.3.9 Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.9.4. Competitive/Market Scenario
      • 6.3.9.5. Regulatory Framework
      • 6.3.9.6. Reimbursement Scenario
      • 6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.2.4. Competitive/Market Scenario
      • 6.4.2.5. Regulatory Framework
      • 6.4.2.6. Reimbursement Scenario
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.3.4. Competitive/Market Scenario
      • 6.4.3.5. Regulatory Framework
      • 6.4.3.6. Reimbursement Scenario
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.4.4. Competitive/Market Scenario
      • 6.4.4.5. Regulatory Framework
      • 6.4.4.6. Reimbursement Scenario
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.5.4. Competitive/Market Scenario
      • 6.4.5.5. Regulatory Framework
      • 6.4.5.6. Reimbursement Scenario
    • 6.4.6. Thailand
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.6.4. Competitive/Market Scenario
      • 6.4.6.5. Regulatory Framework
      • 6.4.6.6. Reimbursement Scenario
    • 6.4.7. South Korea
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.7.4. Competitive/Market Scenario
      • 6.4.7.5. Regulatory Framework
      • 6.4.7.6. Reimbursement Scenario
      • 6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.2.4. Competitive/Market Scenario
      • 6.5.2.5. Regulatory Framework
      • 6.5.2.6. Reimbursement Scenario
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.3.4. Competitive/Market Scenario
      • 6.5.3.5. Regulatory Framework
      • 6.5.3.6. Reimbursement Scenario
      • 6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.2.4. Competitive/Market Scenario
      • 6.6.2.5. Regulatory Framework
      • 6.6.2.6. Reimbursement Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.3.4. Competitive/Market Scenario
      • 6.6.3.5. Regulatory Framework
      • 6.6.3.6. Reimbursement Scenario
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.4.4. Competitive/Market Scenario
      • 6.6.4.5. Regulatory Framework
      • 6.6.4.6. Reimbursement Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.5.4. Competitive/Market Scenario
      • 6.6.5.5. Regulatory Framework
      • 6.6.5.6. Reimbursement Scenario
    • 6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. AbbVie, Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boehringer Ingelheim International GmbH
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Regeneron Pharmaceuticals Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Pfizer, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bristol-Myers Squibb Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F. Hoffmann-La Roche Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. UCB S.A.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Johnson & Johnson Services, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AG Amgen, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Lilly (Eli Lilly and Company)
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 4. Global rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 5. North America rheumatoid arthritis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 6. North America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 7. North America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 8. U.S. rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 9. U.S. rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 10. Canada rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 11. Canada rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 12. Mexico rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 13. Mexico rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 14. Europe rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 15. Europe rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 16. Europe rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 17. UK rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 18. UK rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 19. Germany rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 20. Germany rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 21. France rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 22. France rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 23. Italy rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 24. Italy rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 25. Spain rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 26. Spain rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 27. Norway rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 28. Norway rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 29. Sweden rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 30. Sweden rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 31. Denmark rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 32. Denmark rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 33. Asia Pacific rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 36. Japan rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 37. Japan rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 38. China rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 39. China rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 40. India rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 41. India rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 42. Australia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 43. Australia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 44. South Korea rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 45. South Korea rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 46. Thailand rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 47. Thailand rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 48. Latin America rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 49. Latin America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 50. Latin America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 51. Brazil rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 52. Brazil rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 53. Argentina rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 54. Argentina rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 55. Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 58. South Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 59. South Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 60. Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 62. UAE rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 63. UAE rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 64. Kuwait rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 65. Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Rheumatoid arthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Molecule and sales channel segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global Pharmaceutical Market, (USD billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Rheumatoid arthritis therapeutics: Molecule outlook and key takeaways
  • Fig. 17 Rheumatoid arthritis therapeutics market: Molecule market movement analysis
  • Fig. 18 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 T-cell inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Anti-IL6 biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 DMARDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Glucocorticoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
  • Fig. 34 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
  • Fig. 35 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Over-the-Counter (OTC) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Rheumatoid arthritis therapeutics market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. healthcare system: money flow
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Drug pricing
  • Fig. 47 Key country dynamics
  • Fig. 48 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Regulatory framework
  • Fig. 50 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Italy rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 China rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 China regulatory details
  • Fig. 74 India rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Australia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea reimbursement scenario
  • Fig. 82 Rest of Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil regulation details
  • Fig. 87 Brazil reimbursement scenario
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Argentina regulatory framework
  • Fig. 91 Rest of Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Saudi Arabia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UAE rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Kuwait rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2023 (USD Million)
  • Fig. 100 Rest of MEA rheumatoid arthritis therapeutics market estimates and forecasts,
  • Fig. 101 Company/competition categorization
  • Fig. 102 Company market share analysis, 2023
  • Fig. 103 Strategy mapping